KRAS and non-small cell lung carcinoma: Previous studies have shown that co-mutations of KRAS/STK11 or KRAS/KEAP1 are associated with significantly shorter survival in NSCLC patients [64], with KEAP1/STK11 co-mutations conferring an even worse outcome [65].